Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{172622,
        author = {Mr.Swaraj A. Bramhane and Mr. Vaibhav R. Wagh and Ms.Nikita M. Patil and Mr. Ganesh S. Shelke},
        title = {“Pharmacological Advancements in Rare Diseases: Challenges, Opportunities, and Regulatory Incentives”},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {11},
        number = {9},
        pages = {397-402},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=172622},
        abstract = {The development of pharmacological treatments for rare and orphan diseases represents a critical yet challenging area in modern medicine. Rare diseases, defined as those affecting a small portion of the population, often suffer from a lack of understanding, delayed diagnoses, and limited treatment options. This review explores the multifaceted challenges inherent in drug development for rare diseases, including small and geographically dispersed patient populations, high research and development costs, and complex regulatory requirements. Despite these hurdles, advancements in genomics, precision medicine, and gene therapies have created unprecedented opportunities to address these conditions. Additionally, regulatory frameworks such as the Orphan Drug Act in the United States, the European Medicines Agency’s orphan drug policies, and similar incentives globally play a pivotal role in encouraging innovation. These frameworks provide market exclusivity, tax benefits, and expedited approval pathways, reducing the economic risks for developers. By highlighting both the obstacles and opportunities in this field, this review underscores the importance of collaborative efforts, patient advocacy, and regulatory support in advancing treatments for rare diseases, ultimately aiming to improve patient outcomes and quality of life.},
        keywords = {},
        month = {February},
        }